# Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

> **NCT01576367** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Cryopyrin-associated Periodic Syndromes
- Familial Cold Autoinflammatory Syndrome
- Muckle-Wells Syndrome
- Neonatal Onset Multisystem Inflammatory Disease

## Interventions

- **BIOLOGICAL:** ACZ885

## Key facts

- **NCT ID:** NCT01576367
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-16
- **Primary completion:** 2015-10-13
- **Final completion:** 2015-10-13
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2018-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01576367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01576367, "Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01576367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*